Press Release

<< Back
View printer-friendly version

Spark Therapeutics to Participate in Multiple Conferences in June

PHILADELPHIA, June 01, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today announced that company management will present at or attend several important investment conferences this month.

Specifically, company management will present at:

  • Jefferies 2017 Healthcare Conference on Tuesday, June 6, at 4:00 p.m EDT, at the Grand Hyatt in New York
  • Goldman Sachs 38th Annual Global Healthcare Conference on Wednesday, June 14, at 4:00 p.m. PDT, at the Terranea Resort in Rancho Palos Verdes, Calif.

Company management will also participate in the J.P. Morgan European Healthcare Conference on Thursday, June 22, in London.

About Spark Therapeutics
Spark Therapeutics, a fully integrated company, strives to challenge the inevitability of genetic disease by discovering, developing, and delivering gene therapies that address inherited retinal diseases (IRDs), neurodegenerative diseases, as well as diseases that can be addressed by targeting the liver. Our validated platform successfully has delivered proof-of-concept data with investigational gene therapies in the retina and liver. Our most advanced investigational candidate, voretigene neparvovec, in development for the treatment of biallelic RPE65-mediated IRD, has received orphan designations in the U.S. and European Union, and breakthrough therapy designation in the U.S. The pipeline also includes SPK-7001 in a Phase 1/2 trial for choroideremia, and two hemophilia development programs: SPK-9001 (which also has received both breakthrough therapy and orphan product designations by the FDA, and access to the PRIority MEdicines (PRIME) Program by the EMA) in a Phase 1/2 trial for hemophilia B being developed in collaboration with Pfizer, and SPK-8011, in a Phase 1/2 trial for hemophilia A to which Spark Therapeutics retains global commercialization rights. To learn more about us and our growing pipeline, visit www.sparktx.com.

 

Investor Contact:
Ryan AsayRyan.asay@sparktx.com
(215) 239-6424

Media Contact:
Monique da SilvaMonique.dasilva@sparktx.com
(215) 282-7470

Primary Logo

Spark Therapeutics, Inc.